Navigation Links
Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
Date:8/23/2012

CORK, Ireland and SPRING HOUSE, Pa., Aug. 23, 2012 /PRNewswire/ -- Janssen Biologics (Ireland) announced today it has initiated the Phase 3 development program for sirukumab (CNTO 136) as part of a collaboration with GlaxoSmithKline plc (GSK).  Sirukumab is a human anti-interleukin (IL)-6 monoclonal antibody being studied for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). 

"We are focused on advancing treatment options for chronic, debilitating autoimmune diseases such as rheumatoid arthritis," said Jerome A. Boscia, M.D., Vice President, Head of Immunology Development, Janssen Research & Development, LLC.  "We are pleased to be collaborating with GlaxoSmithKline on the clinical development of sirukumab, a protein therapeutic that we believe may represent an important treatment option for immunological diseases in the future."

The two studies comprising the Phase 3 program are:

  • SIRROUND-T: A multicentre, randomised, double-blind, placebo-controlled, parallel group study of sirukumab administered subcutaneously in subjects with active RA despite anti-tumor necrosis factor (TNF)-alpha therapy. The primary objective is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of RA in subjects with active RA who are refractory or intolerant to anti-TNF-alpha agents.

 

  • SIRROUND-D: A multicentre, randomised, double-blind, placebo-controlled, parallel group study of sirukumab administered subcutaneously in subjects with active RA despite disease modifying anti-rheumatic drug (DMARD) therapy. The primary objective is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of RA and inhibition of radiographic progression in subjects with active RA who are refractory to DMARDs.

About Sirukumab (CNTO 136)
Sir
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
2. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
3. WorkSmart MD Announces Expansion of its Synergy Billing Division to Help Community Health Centers
4. BiOptix Announces Fall 2012 Tradeshow and Symposia Schedule
5. Interventional Spine Announces its 75th Patient Treated with the PerX360 Percutaneous Spinal Fusion Technology
6. Precision Automation Expert DWFritz Automation Announces Website Launch www.DWFritz.com
7. CPhI South America Expands Offering for 2013, Announces Co-Location with Food Ingredients South America
8. EFJohnson Announces Impact Partner Dealer Program
9. Aethlon Medical Announces Renewal of DARPA Dialysis-Like Therapeutics Contract
10. Kallo Announces Purchase Order For Its Specialist EMR - EMCURx
11. CryoLife Announces Initiation of Quarterly Cash Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... results for the second quarter ended June 30, ... see encouraging advancements in the US commercialization of ... total prescriptions and estimated total per week prescriptions ... President and Chief Executive Officer. "Other recent notable ...
(Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 STAAR Surgical ... manufacturer and marketer of implantable lenses and delivery systems ... quarter ended July 4, 2014 of $20.0 million, a ... quarter of 2013. On a constant currency basis, revenues ... to the second quarter of 2013.  The effect of ...
(Date:7/31/2014)... 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... for the quarter ended June 30, 2014. Financial ... 2014 Revenue Total revenue for the quarter ended June ... the quarter ended June 30, 2013 primarily due to IMBRUVICA ... Total revenue for the six months ended June ...
Breaking Medicine Technology:Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26
... 2010 Market Publishers Ltd informs that new in-demand ... been added to its catalogue. ... Devices 2011 . In 2010, the ... and ablation devices were valued at over $1.4 billion. ...
... Dec. 16, 2010 Solta Medical, Inc. (Nasdaq: ... tightening and a market leader in aesthetic skin treatments, today ... revolutionary Thermage and Fraxel devices that have helped to build ... device industry. The milestone reflects how much the ...
Cached Medicine Technology:New Topical Research Reports by iData Research Published by MarketPublishers.com 2New Topical Research Reports by iData Research Published by MarketPublishers.com 3Solta Medical Ships One Millionth Tip for Thermage and Fraxel Devices 2Solta Medical Ships One Millionth Tip for Thermage and Fraxel Devices 3
(Date:8/1/2014)... of electronic reminders such as text messages, emails or ... adhere to a preadmission antiseptic showering regimen known to ... to a first-of-its-kind study published in the August issue ... Surgeons . , Each year approximately 400,000 SSIs occur ... according to data sources cited by study authors. ...
(Date:8/1/2014)... CO (PRWEB) August 01, 2014 According to ... onto the Internet do so in search of information, and ... website, those in search of information and resources on insurance ... , “We're excited to take this next step in the ... DCInsurers Colorado Springs - Commercial Insurance Resources office. ...
(Date:8/1/2014)... Home Care Assistance of Cincinnati , a ... be recognized as a 2014 Best of Home Care Employer ... providers who rank in the top 50th percentile in one ... conducted by Home Care Pulse. , “The Best of ... best of the best!” says Home Care Pulse Founder and ...
(Date:8/1/2014)... Ticket Down is a reputable source for ... in Knoxville/Greenback, TN; Ingram Farms in Auburn/Opelika, AL; Cross Creek ... FL. Luke Bryan is currently out on his summer “That’s ... Swindell. Bryan is responsible for one of the most popular ... year, just because the summer is over doesn’t mean that ...
(Date:8/1/2014)... Researchers and doctors at the Institute of Bioengineering ... National Cancer Centre Singapore (NCCS) have co-developed the ... and survival outcomes in kidney cancer patients. This ... , the world,s top urology journal. , ... Ying, "By combining our expertise in molecular diagnostics ...
Breaking Medicine News(10 mins):Health News:Electronic reminders can help patients prevent surgical site infections 2Health News:Electronic reminders can help patients prevent surgical site infections 3Health News:DCInsurers Agent Doug King Launches a New Website 2Health News:DCInsurers Agent Doug King Launches a New Website 3Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 3Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 4Health News:Taking the guesswork out of cancer therapy 2Health News:Taking the guesswork out of cancer therapy 3
... World Health Organization (WHO), is calling for renewed vigilance against ... Korea, Hong Kong, Indonesia and Vietnam have been reported. There’s ... was probably due to a mutated H5N1 virus that could ... pandemic is overdue and could happen during the winter months. ...
... come out with findings from a study that indicates ... celexa in combating// depression. ,Dr. Fran?ois Lespérance, ... colleagues published their findings in this week’s edition of ... ,The drug celexa, which goes by the generic name ...
... Bilcare, a leading research-based pharmaceutical packing solution ... with Honeywell//, a UK-based pharma packaging firm, ... pharmaceutical sector. ,"The partnership with Honeywell's ... provide state-of-the-art materials for ensuing safety of ...
... maternal DNA in the blood of around 20% of children ... also seemed to help in producing insulin, which is not ... to restore damaged tissue in the pancreas. They also found ... immune system. ,During pregnancy, stem cells of ...
... the high prevalence of HIV/AIDS in Karnataka and hoping to ... Kumaraswamy will spend Tuesday night in the hut of a ... in Bagalkot district, 600 km from the state capital Bangalore ... around 11 p.m. and spend the night in the house ...
... coffee could help cure baldness as caffeine blocks the effects ... ,Tobias Fischer of the University of Jena in Germany took ... hair loss. He extracted hair follicles and placed them in ... ,The samples were left in the laboratory for ...
Cached Medicine News:Health News:Are We Prepared for Flu Pandemic? 2Health News:Citalopram, a Boon in Treating Depressed Heart Patients 2Health News:Karnataka Chief Minister to Spend Night With HIV Positive Family 2
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
.90mm (20G) guillotine cutting probe with 1.4mm (17G) removable irrigation sleeve...
Medicine Products: